NCT01819428 - NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Adenocarcinoma of Lung Stage IIIBAdenocarcinoma of Lung Stage IV

Interventions

DRUG

NOV120101 (Poziotinib)

NOV120101 (Poziotinib)12 mg PO once daily until disease progression or unacceptable toxicity development

Trial Locations (6)

National Cancer Center, Goyang-si

Gachon University Gil Hospital, Namdong-Gu

Samsung Medical Center, Gangnam-gu

Seoul National University Hospital, Jongno-gu

Asan Medical Center, Songpa-gu

Ulsan University Hospital, Dong-gu